Literature DB >> 18411318

In vitro susceptibility of isolates of Francisella tularensis types A and B from North America.

Sandra K Urich1, Jeannine M Petersen.   

Abstract

Due to concern that Francisella tularensis, the causative agent of tularemia, may be used as a bioterrorist weapon, the Clinical and Laboratory Standards Institute recently provided a susceptibility testing method with breakpoints. Here, 169 isolates (92 type A and 77 type B) from North America were tested against seven antimicrobial agents (streptomycin, gentamicin, tetracycline, doxycycline, ciprofloxacin, levofloxacin, and chloramphenicol) used for the treatment of tularemia. The MICs for all of the isolates fell within the susceptible range. In addition, all isolates had MICs for erythromycin of 0.5 to 4 microg/ml, in contrast to an MIC of >256 microg/ml for the common laboratory strain LVS (live vaccine strain).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18411318      PMCID: PMC2415761          DOI: 10.1128/AAC.01584-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals.

Authors:  I Ikäheimo; H Syrjälä; J Karhukorpi; R Schildt; M Koskela
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains.

Authors:  Herbert Tomaso; Sascha Al Dahouk; Erwin Hofer; Wolf D Splettstoesser; Thomas M Treu; Manfred P Dierich; Heinrich Neubauer
Journal:  Int J Antimicrob Agents       Date:  2005-10       Impact factor: 5.283

Review 3.  Tularemia as a biological weapon: medical and public health management.

Authors:  D T Dennis; T V Inglesby; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; M Layton; S R Lillibridge; J E McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; K Tonat
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272

4.  Sensitivity to macrolide antibiotics and lincomycin in Francisella tularensis holarctica.

Authors:  R I Kudelina; N G Olsufiev
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1980

Review 5.  New approaches to diagnosis and therapy of tularemia.

Authors:  Arne Tärnvik; May C Chu
Journal:  Ann N Y Acad Sci       Date:  2007-04-27       Impact factor: 5.691

6.  Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents.

Authors:  O Scheel; T Hoel; T Sandvik; B P Berdal
Journal:  APMIS       Date:  1993-01       Impact factor: 3.205

7.  Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth.

Authors:  C N Baker; D G Hollis; C Thornsberry
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

8.  In vitro susceptibility of field isolates of Francisella tularensis subsp. holarctica recovered in Spain to several antimicrobial agents.

Authors:  N García del Blanco; C B Gutiérrez Martín; V A de la Puente Redondo; E F Rodríguez Ferri
Journal:  Res Vet Sci       Date:  2004-06       Impact factor: 2.534

9.  In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis.

Authors:  Anders Johansson; Sandra K Urich; May C Chu; Anders Sjöstedt; Arne Tärnvik
Journal:  Scand J Infect Dis       Date:  2002

10.  Epidemiologic and molecular analysis of human tularemia, United States, 1964-2004.

Authors:  J Erin Staples; Kristy A Kubota; Linda G Chalcraft; Paul S Mead; Jeannine M Petersen
Journal:  Emerg Infect Dis       Date:  2006-07       Impact factor: 6.883

View more
  21 in total

1.  Multiplex PCR-ligation detection reaction assay for simultaneous detection of drug resistance and toxin genes from Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium.

Authors:  K Granger; M S Rundell; M R Pingle; R Shatsky; D H Larone; L M Golightly; F Barany; E D Spitzer
Journal:  J Clin Microbiol       Date:  2009-10-28       Impact factor: 5.948

2.  AR-13, a Celecoxib Derivative, Directly Kills Francisella In Vitro and Aids Clearance and Mouse Survival In Vivo.

Authors:  Ky V Hoang; Haley E Adcox; James R Fitch; David M Gordon; Heather M Curry; Larry S Schlesinger; Peter White; John S Gunn
Journal:  Front Microbiol       Date:  2017-09-11       Impact factor: 5.640

3.  Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections.

Authors:  Fang-Yi Su; Selvi Srinivasan; Brian Lee; Jasmin Chen; Anthony J Convertine; Timothy Eoin West; Daniel M Ratner; Shawn J Skerrett; Patrick S Stayton
Journal:  J Control Release       Date:  2018-08-09       Impact factor: 9.776

4.  Needle-Free Delivery of Acetalated Dextran-Encapsulated AR-12 Protects Mice from Francisella tularensis Lethal Challenge.

Authors:  Ky V Hoang; Heather Curry; Michael A Collier; Hassan Borteh; Eric M Bachelder; Larry S Schlesinger; John S Gunn; Kristy M Ainslie
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

5.  Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds.

Authors:  Elamparithi Jayamani; Nagendran Tharmalingam; Rajmohan Rajamuthiah; Jeffrey J Coleman; Wooseong Kim; Ikechukwu Okoli; Ana M Hernandez; Kiho Lee; Gerard J Nau; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Evaluation of an immunochromatographic test for rapid and reliable serodiagnosis of human tularemia and detection of Francisella tularensis-specific antibodies in sera from different mammalian species.

Authors:  W Splettstoesser; V Guglielmo-Viret; E Seibold; P Thullier
Journal:  J Clin Microbiol       Date:  2010-03-10       Impact factor: 5.948

7.  Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida.

Authors:  Yvan Caspar; Claire Siebert; Vivien Sutera; Corinne Villers; Alexandra Aubry; Claudine Mayer; Max Maurin; Patricia Renesto
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

8.  [Fever and lymphadenopathy. Report of 4 cases of tularemia].

Authors:  C Bloch; A Friedl; F Zucol; A Widmer; N Khanna
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

9.  Azithromycin effectiveness against intracellular infections of Francisella.

Authors:  Saira Ahmad; Lyman Hunter; Aiping Qin; Barbara J Mann; Monique L van Hoek
Journal:  BMC Microbiol       Date:  2010-04-23       Impact factor: 3.605

10.  In Vitro Antibiotic Susceptibilities of Francisella tularensis Determined by Broth Microdilution following CLSI Methods.

Authors:  Henry S Heine; Lynda Miller; Stephanie Halasohoris; Bret K Purcell
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.